Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Multivariate analyses of characteristics associated with overall survival and progression free survival

From: Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor

Variables OS (n = 110) PFS (n = 107)
Original Variables selected Bootstrapc Original Variables selected Bootstrapc
HR (95%CI) P-valueb HR (95%CI) P-valueb P-valueb HR (95%CI) P-valueb HR (95%CI) P-valueb P-valueb
Histology
 Non-clear cell vs clear cell 2.325 (1.293–4.181) 0.005 2.108 (1.191–3.732) 0.010 0.011 1.717 (1.008–2.926) 0.047 1.606 (0.952–2.710) 0.076 0.087
TNM stage at initial diagnosis
 IV vs I–III 0.990 (0.565–1.736) 0.972     0.988 (0.599–1.631) 0.963    
No. of metastatic sitesa
  ≥ 2 vs 1 1.465 (0.867–2.477) 0.154     1.946 (1.210–3.128) 0.006 1.817 (1.138–2.902) 0.012 0.026
Tyrosine kinase inhibitors
 Sorafenib vs Sunitinib 1.431 (0.861–2.381) 0.167     1.360 (0.858–2.154) 0.191    
Heng’s risk group   <0.001   <0.001 0.005   0.036   0.011 0.035
 Favorable reference   reference    reference   reference   
 Intermediate 1.955 (0.895–4.268)   2.023 (0.964–4.244)    1.212 (0.634–2.313)   1.297 (0.701–2.398)   
 Poor 5.654 (2.267–14.103)   6.760 (2.932–15.587)    2.432 (1.095–5.398)   2.771 (1.326–5.788)   
Tumoral CCR7
 High vs Low 2.242 (1.288–3.901) 0.004 2.256 (1.336–3.809) 0.002 0.003 1.782 (1.105–2.875) 0.018 1.835 (1.156–2.912) 0.010 0.013
  1. Bold data means statistical significant (P<0.05)
  2. HR Hazard Ratio, CI confidence interval, OS overall survival, PFS progression free survival
  3. P-value <0.05 was regarded as statistically significant
  4. aAt the time initializing tyrosine kinase inhibitors
  5. bData obtained from the Cox proportional hazards model
  6. cBootstrapping with 1000 resamples were used